ArticleBMC cancer2021
Clinical characteristics and risk factors associated with Pneumocystis jirovecii infection in patients with solid tumors: study of thirteen-year medical records of a large cancer center.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review.Future oncology (London, England) · 2025Pooled it
- Pneumocystis Pneumonia in a Patient Receiving Nab-paclitaxel Plus Gemcitabine for Unresectable Pancreatic Cancer.Internal medicine (Tokyo, Japan) · 2026Article
- A Rare Case of Concurrent Tropheryma Whipplei and Pneumocystis Jirovecii Pneumonia in a Patient During Endocrine Therapy for Breast Cancer.Infection and drug resistance · 2026Article
- Clinical analysis of Pneumocystis jirovecii pneumonia in children with malignant disease.BMC pediatrics · 2025Article
- Clinical characteristics and prognostic analysis of concurrent Pneumocystis jirovecii pneumonia in patients with malignancies: a retrospective study.BMC infectious diseases · 2025Article
- Association of peripheral-blood neutrophil-to-lymphocyte ratio withJournal of thoracic disease · 2025Article
- Diagnostic value of nanopore-based metagenomic third-generation sequencing in the diagnosis ofJournal of medical microbiology · 2025Observational
- Development and assessment of a mortality risk prediction nomogram model for pneumocystis disease in ICU within 28 days.Scientific reports · 2025Article
- Case Report: FatalCase reports in oncological medicine · 2025Article
- Clinical features, pathogens, and prognosis of immunocompromised host pneumonia in patients with malignancies.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Article
- Immune checkpoint inhibitor increased mortality in lung cancer patients withFrontiers in oncology · 2024Article
- Re-challenging pralsetinib following recovery from pneumocystis jirovecii pneumonia in a lung cancer patient: a Case Report.Frontiers in pharmacology · 2024Article
- Visualization of the relationship between fungi and cancer from the perspective of bibliometric analysis.Heliyon · 2023Article
- Trends in the Epidemiology ofJournal of fungi (Basel, Switzerland) · 2023Review
- Study on the Prevalence ofBiomedicines · 2023Article
- Pneumocystis jirovecii pneumonia in a patient treated with trastuzumab-deruxtecan.BMJ case reports · 2023Article
- Pneumocystis Pneumonia in a Non-Immunocompromised Lung Cancer Patient after Surgery: A Case Report.Healthcare (Basel, Switzerland) · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPneumocystis jirovecii pneumonia (PCP)-related risk factors among patients with solid tumors are not completely defined. Thus, we aimed to characterize PCP cases with underlying solid tumors, to highlight the factors contributing to its development besides the prolonged use of moderate-to-high dose corticosteroids.
methodsWe retrospectively reviewed the medical records of patients with solid tumors diagnosed with PCP between 2006 and 2018 at a cancer center in Tokyo, Japan. Demographic and clinical data were collected, which included malignancy types, total lymphocyte count, coexisting pulmonary disease, chemotherapy, radiation therapy, corticosteroid use, and PCP-attributable mortality.
resultsTwenty cases of PCP with solid tumors were documented in 151,718 patients and 788,914 patient-years. Lung cancer (n = 6, 30%) was the most common underlying tumor, followed by breast cancer (n = 3, 15%). Only six (30%) patients were taking a dosage of ≥20 mg prednisone equivalents daily for ≥4 weeks from the onset of PCP. Among the remaining 14 patients, seven (50%) had coexisting pulmonary diseases, 10 (71%) had received chemotherapy within 90 days prior to PCP diagnosis, seven (50%) had undergone chest radiation therapy before PCP diagnosis, seven (50%) had received only intermittent corticosteroids, and one (7%) received no corticosteroids. Mortality attributable to PCP was 40%.
conclusionsMore than half of the patients were not taking a dosage of ≥20 mg prednisone equivalents daily for ≥4 weeks. Multiple other factors (e.g., lymphocytopenia, radiation to chest) may have potentially contributed to PCP in patients with solid tumors in a composite manner. We need to establish a method for estimating the likelihood of PCP taking multiple factors into account in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.